Search Result

Results for "

iron overload

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bacterial (4) Biochemical Assay Reagents (3) Fatty Acid Synthase (FASN) (1) Ferrochelatase (1) Ferroptosis (8) HCV (1) Isotope-Labeled Compounds (3) NO Synthase (1) Reference Standards (1) Ser/Thr Protease (1) TGF-beta/Smad (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (4) Metabolic Disease (2)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Ferroportin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17359

Deferasirox 5+ Cited Publications ICL 670	Bacterial Ferroptosis	Cancer
Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .

HY-108260

Deferitrin GT-56-252	Ferroptosis	Cardiovascular Disease
Deferitrin (GT-56-252), a desferrithiocin (DFT) analogue, is an orally active trident iron chelator. Deferitrin is used for chronic iron overload due to transfusional therapy. Deferitrin has the potential for beta-thalassemia major .

HY-114837

HBED	Ferroptosis	Cancer
HBED is a potent iron chelator. HBED can be used to study transfusional iron overload .

HY-B1645

Ammonium iron(III) citrate Maximum Cited Publications 17 Publications Verification Ammonium ferric citrate; FAC	Ferroptosis	Cancer
Ammonium iron(III) citrate (Ammonium ferric citrate), a physiological form of nonetransferrin-bound iron, induces intracellular iron overload to cause ferroptosis . Ammonium iron(III) citrate can enhance protein production .

HY-B0568S

Deferiprone-d3	Isotope-Labeled Compounds HCV Ferroptosis	Cardiovascular Disease Cancer
Deferiprone-d₃ is the deuterium labeled Deferiprone. Deferiprone is the only orally active iron-chelating agent to be used therapeutically in conditions of transfusional iron overload .

HY-108194

CGP 46700	Biochemical Assay Reagents	Others
CGP 46700 (Compound 49) is an orally active iron chelator, that exhibits high affinity for iron, removes iron from ferritin and human serum transferrin. CGP 46700 promotes iron excretion in a mouse iron overload model .

HY-17359S

Deferasirox-d4	Isotope-Labeled Compounds Bacterial Ferroptosis	Cancer
Deferasirox-d₄ is the deuterium labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .

HY-P991137

Exerenibart	Ser/Thr Protease	Metabolic Disease
Exerenibart is an immunoglobulin G4-κ monoclonal antibody targeting human transmembrane serine protease 6 (TMPRSS6). Exerenibart is promising for research of diseases associated with iron metabolism disorders, such as iron overload or iron deficiency .

HY-17359R

Deferasirox (Standard) ICL 670 (Standard)	Reference Standards Bacterial Ferroptosis	Cancer
Deferasirox (Standard) is the analytical standard of Deferasirox. This product is intended for research and analytical applications. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .

HY-17359S1

Deferasirox-13C6 ICL 670-¹³C₆	Isotope-Labeled Compounds Ferroptosis Bacterial	Cancer
Deferasirox- ¹³C₆ (ICL 670- ¹³C₆) is ¹³C labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .

HY-W339484

1-Ethyl-2-methyl-3-hydroxypyrid-4-one	Biochemical Assay Reagents	Others
1-Ethyl-2-methyl-3-hydroxypyrid-4-one is an α-ketohydroxypyridinium iron chelator with high specificity for iron and no specific activity against other metal ions such as copper, zinc, calcium and magnesium. In rabbits with iron overload, 1-Ethyl-2-methyl-3-hydroxypyrid-4-one increased iron excretion after oral or parenteral administration.

HY-114758

Pyridoxal isonicotinoyl hydrazone 4 Publications Verification	Biochemical Assay Reagents Ferrochelatase	Cardiovascular Disease
Pyridoxal isonicotinoyl hydrazone is an orally active and lipophilic iron-specific chelator that acts as a non-competitive inhibitor of ferrochelatase (FECH) by binding iron ions. Pyridoxal isonicotinoyl hydrazone disrupts heme biosynthesis, leading to reduced FECH stability and increased protoporphyrin IX (PPIX) accumulation. Pyridoxal isonicotinoyl hydrazone is promising for research of iron-overload diseases (e.g., β-thalassemia) .

HY-111914A

Ferroheme	NO Synthase Fatty Acid Synthase (FASN)	Cardiovascular Disease
Ferroheme is the ferrous form of heme in hemoglobin, reversibly binding oxygen as an oxygen carrier. Its free form induces oxidative stress and ferroptosis by releasing iron ions, which catalyze reactive oxygen species generation via Fenton reactions, leading to lipid peroxidation and cell death. This mechanism is critical in pathological contexts like intracerebral hemorrhage and neurodegenerative diseases, making it a target for studying iron-overload disorders and ferroptosis-related pathologies[1][2][3].

HY-P99720A

Luspatercept (mIgG2a) RAP-536	TGF-beta/Smad	Metabolic Disease
Luspatercept (mIgG2a) (RAP-536) is a fusion protein, consisting of a modified extracellular domain of human ActRIIB linked to the murine IgG2a Fc domain. Luspatercept (mIgG2a) inhibits Smad2/3 signaling, promotes differentiation of late-stage erythroid precursors and mitigates ineffective erythropoiesis (IE) in murine β-thalassemia. Luspatercept (mIgG2a) reduces anemia, α-globin aggregates, hemolysis, and disease complications of IE such as iron overload, splenomegaly, and bone defects .

Cat. No.	Product Name	Target	Research Area

HY-P991137

Exerenibart	Ser/Thr Protease	Metabolic Disease
Exerenibart is an immunoglobulin G4-κ monoclonal antibody targeting human transmembrane serine protease 6 (TMPRSS6). Exerenibart is promising for research of diseases associated with iron metabolism disorders, such as iron overload or iron deficiency .

HY-P99720A

Luspatercept (mIgG2a) RAP-536	TGF-beta/Smad	Metabolic Disease
Luspatercept (mIgG2a) (RAP-536) is a fusion protein, consisting of a modified extracellular domain of human ActRIIB linked to the murine IgG2a Fc domain. Luspatercept (mIgG2a) inhibits Smad2/3 signaling, promotes differentiation of late-stage erythroid precursors and mitigates ineffective erythropoiesis (IE) in murine β-thalassemia. Luspatercept (mIgG2a) reduces anemia, α-globin aggregates, hemolysis, and disease complications of IE such as iron overload, splenomegaly, and bone defects .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1645

Ammonium iron(III) citrate 15+ Cited Publications Ammonium ferric citrate; FAC	Ketones, Aldehydes, Acids Source classification Rutaceae Plants Disease Research Fields Citrus reticulata Blanco Cancer	Ferroptosis
Ammonium iron(III) citrate (Ammonium ferric citrate), a physiological form of nonetransferrin-bound iron, induces intracellular iron overload to cause ferroptosis . Ammonium iron(III) citrate can enhance protein production .

HY-111914A

Ferroheme	Alkaloids Human Gut Microbiota Metabolites Microorganisms Pyrrole Alkaloids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	NO Synthase Fatty Acid Synthase (FASN)
Ferroheme is the ferrous form of heme in hemoglobin, reversibly binding oxygen as an oxygen carrier. Its free form induces oxidative stress and ferroptosis by releasing iron ions, which catalyze reactive oxygen species generation via Fenton reactions, leading to lipid peroxidation and cell death. This mechanism is critical in pathological contexts like intracerebral hemorrhage and neurodegenerative diseases, making it a target for studying iron-overload disorders and ferroptosis-related pathologies[1][2][3].

Cat. No.	Product Name	Chemical Structure

HY-B0568S

Deferiprone-d3
Deferiprone-d₃ is the deuterium labeled Deferiprone. Deferiprone is the only orally active iron-chelating agent to be used therapeutically in conditions of transfusional iron overload .

HY-17359S

Deferasirox-d4
Deferasirox-d₄ is the deuterium labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .

HY-17359S1

Deferasirox-13C6
Deferasirox- ¹³C₆ (ICL 670- ¹³C₆) is ¹³C labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

iron overload

Inhibitors & Agonists

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products